1Anand IS,Fisher LD,Chiang YT, et al.Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT) [J]. Circulation,2003,107 (9); 1278-1283.
2Yasuaki D, Masuo O, Masaya A, et al.Candesartan reduces oxidative stress and inflammation in patients with essential Hypertension. hypertens Res, 2003, 26:691-697.
3Oparil S. Newly emerging pharmacologic differences in angiotensinⅡ receptor blockers[J]. Am J Hypert,2000,13:18S.
4Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for endpoint reduction in hypertension study(LIFE): a randomized trial against atenolol [J] .Lancet, 2002,359: 995-1003.
5Julius S, Kjeldsen SE, Weber M. VALUE trial group. outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial[J]. Lanc et, 2004,363 ( 9426 ): 2022-2031.
6Nelson MR, Reid CM, Krum H, et al.Short-term predictors of maintenance of normotension after withdrawal of antigypertensive drugs in the second Australian national blood pressure study(ANBP2) [J] . Am J Hypertens, 2003Jan, 16(1);39-45.
7Pitt B, Segal R, Martinez FA, On behalf of ELITE study investigators. Randomized trial of losartan versus cap in patients over 65 with heart failure(Evaluatiotopril3n of losartan in the elderly study. ELITE) [J] .Lancet, 1997,349:747-752.
8Pitt B,Poole-Wilson PA, Se gal R, et al.Effect of Losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan heart failure survival study ELITE Ⅱ[J] . Lancet, 2000, 355:1582-1587.
9Cohn JN, Tognoni G. 4 Valsartan heart failure trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure[J] . N Engl J Med, 2001,345: 1667-1675.
10Pfeifer MA, S wedberg K. The CHARM investigators and committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme [J] . Lancet,2003,362(9386) :759-781.
